11 May 2021 : Original article
Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in Liver Transplant Patients
Yong Ho Jeong1ABCDEFG, Shin Hwang2ACDEF, Geun Dong Lee1AB, Se Hoon Choi1AB, Hyeong Ryul Kim1AB, Yong-Hee Kim1AB, Seung-Il Park1AB, Dong Kwan Kim1ABCDEFG*DOI: 10.12659/AOT.930383
Ann Transplant 2021; 26:e930383
Table 2 Recurrence and survival status of patients who underwent pulmonary metastasectomy.
| Parameter | Value |
|---|---|
| Follow-up period after LT, mean±SD (median, range), year | 5.4±4.1 (4.0, ~0.2–14.2) |
| Current status | |
| Alive without further recurrence | 7 (13.5%) |
| Alive with further recurrence | 10 (19.2%) |
| Non-cancer-related death without recurrence | 11 (21.2%) |
| Cancer-related death | 24 (46.2%) |
| Recurrence after metastasectomy | 34 (65.4%) |
| Recurrence at more than two sites after metastasectomy | 16 (30.2%) |
| Recurrence-free period after metastasectomy, mean±SD (median, range), year | 1.7±2.4 (0.6, ~0.1–12.0) |
| Initial recurrence site after metastasectomy | |
| Lung | 25 (48.1%) |
| Liver | 10 (19.2%) |
| Others (brain, other gastrointestinal organs, bone, etc) | 20 (38.5%) |
| LT – liver transplantation. Results reported as n (%), unless otherwise indicated. | |